Psilocybin is not suitable for everyone. Clinical trials, retreat screening forms, and public health agencies agree on a core list of conditions and medications that should stop participation before any session begins. Understanding absolute contraindications is not about fear. It is about matching a powerful serotonergic experience to a body and mind that can metabolize it safely. This article explains the psychiatric and medical categories that responsible providers treat as hard stops, why they exist, and how they differ from relative precautions that may allow participation only after specialist review.
Absolute contraindications are conditions where the expected risk outweighs any potential benefit in non-medical or retreat settings. They appear in protocols from Johns Hopkins psychedelic research, FDA briefing documents for psilocybin trials, and screening tools used by legal truffle retreats in the Netherlands. If you are comparing retreat options, start with our overview of health contraindications and read this article as a deeper reference on the strictest exclusions.
What makes a contraindication absolute
In medicine, contraindications are ranked as absolute or relative. An absolute contraindication means the intervention should not proceed under any routine circumstance. A relative contraindication means caution, additional monitoring, or specialist clearance may be appropriate. Psilocybin amplifies perception, mood, and autonomic arousal. That profile makes certain psychiatric histories and cardiovascular states unsafe because the substance can trigger mania, psychosis, hypertensive spikes, or dangerous drug interactions without warning.
Retreat organizers are not hospitals. They rely on honest self-reporting and sometimes follow-up questions. Omitting a diagnosis or medication on a form does not remove the biological risk. It only removes the facilitator's ability to protect you. The lists below reflect consensus across academic trials and harm reduction literature, including summaries from the European Monitoring Centre for Drugs and Drug Addiction on psychedelic health risks.
Psychiatric absolute contraindications
Personal or family history of schizophrenia or psychotic spectrum disorders. Psilocybin can produce perceptual changes that resemble psychotic symptoms. People with genetic or personal vulnerability may experience prolonged or destabilizing episodes. Trials routinely exclude these histories. See our dedicated article on schizophrenia spectrum and psychedelics for the clinical reasoning.
Bipolar I disorder or bipolar spectrum with mania risk. Serotonergic psychedelics may precipitate manic episodes, especially without mood stabilizers or with recent instability. Bipolar II and cyclothymia are often treated as relative contraindications requiring psychiatrist clearance, but many retreats exclude all bipolar diagnoses. Our article on bipolar disorder and psilocybin explores mania risk in more detail.
Current severe depression with active suicidality or recent hospitalization. Clinical psilocybin therapy may help treatment-resistant depression in supervised medical settings, but unstructured retreats are inappropriate when acute safety cannot be guaranteed. Facilitators need stable baselines to support difficult material without crisis escalation.
Borderline personality disorder with self-harm, dissociation, or unstable relationships. Not every trial lists personality disorders as absolute exclusions, but many retreat programs do because intense experiences can overwhelm coping skills. This is often classified as relative in research yet absolute in consumer retreat screening.
Medical and cardiovascular contraindications
Uncontrolled hypertension, recent heart attack, heart failure, or significant arrhythmia. Psilocybin can raise blood pressure and heart rate during the peak. People with compromised cardiovascular systems face elevated strain. Stable, treated hypertension may be a relative contraindication with physician approval. Uncontrolled cases are absolute. Read more in our guide to heart conditions and psilocybin.
Pregnancy and breastfeeding. There is no adequate human safety data for psilocybin during pregnancy or lactation. Animal data are insufficient for risk-benefit analysis. Responsible providers exclude pregnant and breastfeeding participants entirely. We cover the evidence gap in our article on pregnancy, breastfeeding, and psilocybin.
Severe liver or kidney disease. Metabolism and clearance may be altered, increasing unpredictability. Trials often exclude significant hepatic impairment. Kidney disease matters when dehydration or fasting is part of retreat preparation.
Active seizures or uncontrolled epilepsy. Although psilocybin is not classic pro-convulsant like some stimulants, altered states can interact with seizure thresholds in poorly controlled epilepsy. Neurology clearance is mandatory where participation is considered at all.
Medication contraindications
Lithium. Combined use with psychedelics has been associated with seizures and severe reactions in case reports. Lithium is widely treated as an absolute contraindication. See lithium and psychedelics for mechanism and documentation.
Tramadol and certain opioids. Tramadol has serotonergic activity and raises serotonin syndrome risk when combined with psilocybin. Some opioids also affect serotonin pathways. Our article on tramadol, opioids, and psilocybin explains warning signs.
MAO inhibitors. Though less common today, MAOIs dramatically alter psilocybin potency and cardiovascular risk. They remain absolute contraindications in virtually every protocol.
High-dose SSRIs and some antidepressants. Research settings sometimes taper medications; retreats typically exclude recent changes or combined use because outcomes are unpredictable and blunting may push people toward higher doses. Always discuss psychiatric medications with a prescriber. Never stop medication solely to attend a retreat.
Substance use and acute states
Active substance dependence, acute intoxication, or withdrawal from alcohol or benzodiazepines are absolute contraindications. Psychedelics do not substitute for detox support. Combining cannabis, alcohol, or other drugs with psilocybin increases adverse events. Harm reduction guidance from the Multidisciplinary Association for Psychedelic Studies emphasizes sober facilitation and substance-free windows before sessions.
Recent traumatic events, acute grief without support, or psychotic-level sleep deprivation also function as practical absolute stops even if they are not diagnoses. Facilitators need participants who can consent clearly and maintain orientation to time and place.
How clinical trials define exclusions
Published psilocybin trials provide the most transparent exclusion criteria. A landmark methods paper by Johnson and colleagues lists psychiatric, medical, and medication exclusions that inform modern retreat screening. Trial lists are stricter than casual use because researchers must minimize confounding and protect vulnerable participants. Retreats that mirror trial exclusions are not being overly cautious. They are applying evidence-based boundaries outside a hospital.
The FDA's public materials on psychedelic trial design similarly stress cardiovascular monitoring, psychiatric stability, and medication washout periods. Consumer retreats rarely offer ECG monitoring or inpatient backup. That gap is why absolute contraindications matter more in retreat tourism than in supervised therapy.
Absolute versus relative: a practical table
Absolute exclusions commonly include psychotic spectrum disorders, bipolar I with mania history, lithium use, MAOIs, pregnancy, uncontrolled heart disease, and active suicidality. Relative exclusions often include stable hypertension, SSRIs without recent changes, distant single depressive episodes, and well-controlled anxiety with prescriber approval. Retreat policies vary. Two programs labeled "medical screening" may disagree on borderline cases. Ask for written criteria before paying deposits.
Relative does not mean optional. It means you need a clinician who understands both your chart and psychedelic pharmacology. General practitioners unfamiliar with psilocybin may reasonably decline to sign clearance. Seek specialists or psychiatrists experienced in integration and psychedelic medicine where available.
Why honesty on screening forms protects everyone
Screening protects the participant, other guests, and staff. A medical emergency in a rural venue consumes resources and traumatizes the group. Facilitators who discover withheld information may stop the session or ask someone to leave without refund, not from punishment but from safety obligations. Legal truffle retreats in the Netherlands still operate under duty-of-care norms even when psilocybin truffles are lawful to sell.
If you fail screening, that answer is information. It may point toward therapy, stabilization, or medical psilocybin trials in the future rather than recreational retreat culture. Integration coaches, somatic therapists, and meditation retreats without substances remain legitimate paths for personal growth.
Screening form design and false negatives
Well-designed questionnaires use plain language for psychiatric terms and ask about hospitalizations, medications, and family history separately. Guests who misunderstand bipolar II as mild depression may answer no incorrectly. Facilitators should offer clarification calls before final approval. False negatives endanger groups when manic episodes disrupt shared space.
Periodic policy review aligns retreat lists with updated trial exclusion criteria published in peer-reviewed journals. Operators citing decade-old blog posts should update when FDA briefing documents change.
Questions to ask any retreat before booking
Request their written contraindication list and ask how they handle disclosed medications. Confirm whether a nurse or physician is on call, what hospital transport protocol exists, and whether they exclude conditions you carry. Compare their list to the categories above. Meaningful differences should be explained, not brushed aside. Also review preparation guidance on magic truffles and the retreat experience page to understand setting expectations.
Conclusion
Absolute contraindications for psilocybin exist because the molecule is powerful, the setting is usually non-clinical, and serotonergic drugs interact with mood, perception, and the cardiovascular system. Psychotic spectrum disorders, bipolar mania risk, pregnancy, uncontrolled heart disease, lithium, MAOIs, tramadol, acute suicidality, and active addiction belong on the hard-stop list for most responsible programs. Relative cases demand individualized medical review, not self-assessment after reading online forums.
Use this article alongside our contraindications hub, share accurate information with facilitators, and treat exclusion as care rather than rejection. Safety screening is the foundation of ethical psychedelic education, whether you participate in a retreat or support someone who is considering it.
When guidelines change
Medical consensus evolves as trials publish new data. A condition excluded today may become a monitored inclusion in hospital protocols tomorrow. Retreat policies typically change more slowly and err on the side of caution. Subscribe to primary sources such as peer-reviewed journals and regulator updates rather than social media anecdotes. If your situation is borderline, document conversations with your clinician and ask retreats whether medical letters influence final decisions. Written policies protect both parties when outcomes are uncertain.
UNLOCK THE MIND. ELEVATE THE SELF.
